Metabolomics and lipidomics: The use of high-end mass spectrometry methodologies to interrogate the metabolome and lipidome to uncover novel mechanisms of drug and environmental chemical toxicity. Determination of metabolic biomarkers for liver disease progression, including fibrosis, cirrhosis, and hepatocellular carcinoma. Impact of HCV infection on the metabolome and lipidome, the role of AKR1B genes and their relationship to liver disease.
Neurodegenerative diseases, cancer and drug discovery: investigating naturally-based products for neuroprotective signaling mechanisms in Alzheimer and Parkinson diseases, and anticancer effects in glioblastoma. Primary focus is identifying biomarkers for drug development and potential therapeutic applications.
Primary Care/Family Medicine/Global Health: Pharmacist’s role in chronic disease state management, including diabetes, lipids, hypertension, and others; Chronic disease state management in patients living with HIV/AIDS; Safe and efficacious use of anticoagulant therapy; Qualitative research on patient perceptions and understanding of health risk associated with chronic disease states; Capacity building for chronic disease state management in global health settings; Impact of incorporating global health education into pharmacy curriculums.
Research Interests: Infectious Diseases: Discovery of ideal antimicrobial regimens for multidrug resistant bacteria, including penicillin-resistant ampicillin-susceptible Enterococcus faecalis and Klebsiella pneumoniae. Identification of antimicrobial pharmacodynamic targets through in vitro modeling. Clinical translation of in vitro findings to advance therapeutic drug monitoring practices.
Professor of Pharmaceutics
Division of Pharmaceutical Sciences Bhaskar.Das@liu.edu
New methodologies for carbon-boron bond formation to synthesize boron-containing unnatural amino acids for use in cancer therapy. Synthesis of chemical libraries of boron-containing agents for use in the treatment of brain cancer and neurodegenerative diseases. Development of chemical libraries of PET and SPECT imaging agents for non-invasive diagnoses of Alzheimer's disease and brain cancer. Development of new therapeutic and diagnostic agents for brain cancer, prostate cancer, obesity and cardiovascular diseases.
Pharmaceutical Pre-formulation and Formulation: My major research interest is in the area of solid dosage forms and developing new technologies for delivery of poorly-soluble drugs. In the past few years, nanotechnology has been a focus of my laboratory, especially the incorporation of drugs into oral films for better bioavailability and ease of administration. Another area of interest is in powder characterization, to understand the behavior of powder during the pre-formulation step and its changes during the scale-up process. We are continuously working with many generic companies to develop complex solid generics and strategies to bypass the patents associated with it.
Research Interests: International pharmacy practice in resource poor settings, program development, health profession education and training challenges, sustainable solutions, workforce strengthening, capacity building in resource poor countries. International pharmacy practice experiences for pharmacy students. Student perceptions on learning, best practices for teaching various learning styles, higher cognitive level assessments. Improving patient care through increase in pharmacy involvement in outpatient services.
My pharmaceutical material science laboratory investigates the impact of physico-mechanical properties of drug formulation components on the performance of the final pharmaceutical dosage form. Our published “DM3” approach combines an understanding, evaluation, and prediction of the interplay of molecular and macroscopic properties of materials (M1) and manufacturing parameters (M2) on the final dosage form performance, using design of experiments (D) and advanced statistical techniques such as multivariate analysis (M3).
Precision Medicine: Elucidation of the factors that determine individuality in response to therapeutic agents and environmental chemical exposures; in particular, how these responses are genetically controlled and expressed through the metabolome and lipidome. Development of predictive biomarkers of disease diathesis and drug response using gene expression and mass spectrometry.
Radiation metabolomics: Development of protocols, and ultimately a device, to determine absorbed doses of ionizing radiation using metabolomics. These would be used to triage populations exposed to mass radiation releases, either accidental or deliberate.
Cardiovascular Pharmacology, Lung Biology: Main research focus is cardiopulmonary pharmacology and the interaction between reactive airway diseases and development of cardiovascular diseases (CVD); asthma/COPD pathogenesis; role of angiotensin ll and adenosine in lung diseases and CVD. Identifying novel vascular smooth muscle and endothelial derived-relaxing factors, signaling mechanisms and dysfunction in CVD; population and epidemiological basis of the correlation between lung function and stroke, hypertension and atherosclerosis.
Avinash Kumar, Ph.D.
Assistant Professor, Cancer Research Laboratories
Director, Small Animal Imaging Core
Division of Pharmaceutical Sciences Avinash.Kumar@liu.edu
Molecular cell biology and pharmacology of prostate cancer: MTA1-mediated signaling in prostate cancer progression and metastasis, MTA1-associated miRNAs in prostate cancer biology, MTA1 and miRNA-targeted efficacy of dietary stilbenes in prostate cancer chemoprevention and treatment.
Current projects: Understanding the role of MTA1 in prostate cancer progression and bone metastasis using transgenic and xenograft mouse models, determining the MTA1 inhibitory property of FDA approved chemotherapeutic agents for treatment of prostate cancer and elucidating the MTA1-targeted efficacy of combinatorial approaches for treatment of prostate cancer.
John M. Lonie, R.Ph., Ed.D.
Associate Professor, Social and Administrative Sciences
Director, Interdisciplinary Studies
Program Director, Drug Regulatory Affairs
Division of Pharmaceutical Sciences John.Lonie@liu.edu
Social Pharmacy: Factors affecting empathic and emotional development in pharmacy students and pharmacists; improving patient outcomes using novel methodologies to measure, predict and improve medication adherence. Current project: Design and evaluation of the impact of a specialized pharmacist training program geared toward improving patient antidepressant medication adherence.
Research Interests: Dr. Mo’s research interests involve all aspects of critical care including pain/agitation/delirium practices, sepsis, infectious diseases, anticoagulation/hemostasis management, and alcohol withdrawal syndrome. Clinical research projects currently in progress include a survey study on current practice patterns in the management of alcohol withdrawal syndrome and a retrospective cohort study evaluating the effect of modafinil on cognitive function in intensive care unit patients.
Pharmaceutical Material Science: Physico-chemical properties of formulation components on the performance of the final pharmaceutical dosage form. These properties include particle size, shape, surface area, and charge; crystal structure, lattice energy, forms (i.e., polymorphs and hydrates), morphology; relative crystallinity (and amorphous content); hygroscopicity; solubility. A focus of our research is the use of advanced analytical techniques to follow these properties throughout the manufacturing process. The techniques include powder and single crystal x-ray diffraction, differential scanning calorimetry, thermal gravimetric analysis, mid- and near-diffuse reflectance Fourier transform infra-red spectrophotometry, dielectric spectroscopy, and molecular and crystallographic modeling.
Mental Health Disorders: Clinical management of attention-deficit hyperactivity disorder; mood disorders, especially depression and bipolar disorders; sleep disorders, emphasis on insomnia. Drug-Induced movement disorders, their management and legal implications. Current interest in social and psychological aspects of health behavior.
Drug Information Services/Resources and Health and Drug Literacy of Professionals and Consumers: The continuous evolution of drug information centers in the US, information resources used by healthcare professionals and consumers, health literacy of healthcare professionals and consumers as it relates to pharmaceuticals and dietary supplements.
Scholarship of Teaching and Learning: Developing, implementing, and evaluating novel approaches to teach biomedical science, research methods, and communication skills.
Current projects: Development of a biochemistry research elective Advanced Pharmacy Practice Experience, evaluating the impact of order of didactic and experiential learning on student understanding of scientific concepts, and evaluation of the use of improvisational activities to teach communication skills in a pharmacy practice lab course.
Cancer Research and Drug Discovery: Examination of the biological activities of natural products via a set of in vitro assays, and mechanistic studies on the potent compounds or extracts using in vivo models. Current project: To investigate the effect of daily intake of grapes on health and longevity.
HIV/AIDS and Hepatitis C: Involved in evaluating the management of patients living with HIV/Hepatitis C and their comorbidities. Pharmacy Practice in Ambulatory Care Settings: Evaluating the impact clinical pharmacists have on patient care in improving individual and public health outcomes.
Pharmaceutical Sciences: Cutaneous microdialysis, topical and transdermal delivery, in vitro / in vivo correlations, bioequivalence of topical formulations, pharmacokinetics and pharmacodynamic modeling. A specific focus of our research is the use of microdialysis to study the rate and extent of drug delivery to the skin from topical/transdermal devices (iontophoresis, microneedles) and formulations, and from systemic administrations.
Pharmacokinetics and Biopharmaceutics: Research centers on application of in vitro, in vivo and in silico tools to evaluate absorption, distribution, metabolism and excretion. This includes application of perfused organ systems (kidney, intestine, liver) to characterize drug disposition mechanisms and in vivo experiments to evaluate the pharmacokinetics of novel compounds following various routes of administration. These studies are used to support the development of novel drug formulations or to assess potential drug:drug interactions. Computer-based modeling and simulation techniques are used to predict plasma drug levels in humans from preclinical data (IVIVE), to correlate in vitro and in vivo data (IVIVC), to assess pharmacokinetics in special populations, or to provide pharmacokinetic analysis of data generated from clinical studies.
Research interests have revolved around the use of drug information resources by both healthcare professionals and the lay public, and global topics relevant to clinical pharmacy practice. More recently, research has centered on educational practices as they pertain to programmatic and curricular assessment. Current focus is on the use of standardized patients in improving students' pharmacy practice skills.
Join the LIU Community!
We can't wait to welcome you to Shark Nation.
The application process is quick and easy, but if you have
any questions, our admissions counselors are here to help.